ARTICLE | Clinical News
Livatag doxorubicin Transdrug regulatory update
May 26, 2014 7:00 AM UTC
BioAlliance said FDA granted Fast Track designation to Livatag to treat hepatocellular carcinoma (HCC) after treatment with sorafenib. The nanoparticle formulation of doxorubicin is in the Phase III R...